Optical Metabolic Imaging of Treatment Response in Human Head and Neck Squamous Cell Carcinoma
Optical Metabolic Imaging of Treatment Response in Human Head and Neck Squamous Cell Carcinoma
复制标题
DOI：
10.1371/journal.pone.0090746
复制
发表时间：
2014-03-04
期刊：
影响因子：
3.7
通讯作者：
Skala, Melissa C.
中科院分区：
文献类型：
--
作者：
Shah, Amy T.;Beckler, Michelle Demory;Skala, Melissa C.
光学代谢成像测量代谢辅助因子烟酰胺腺嘌呤二核苷酸(NADH)和黄素腺嘌呤二核苷酸(FAD)的荧光强度和寿命。这些分子水平的测量为癌症治疗的早期细胞反应提供了独特的生物标记物。头颈部鳞状细胞癌(HNSCC)是一个有吸引力的光学成像目标，因为它很容易使用光纤探头进入部位。用抗EGFR抗体西妥昔单抗、PI3K/mTOR抑制剂BGT226或化疗药物顺铂处理HNSCC细胞株SCC25和SCC61 24小时。结果显示，与非恶性细胞系OKF6相比，恶性肿瘤细胞的氧化还原比、NADHα(1)(来自游离NADH的贡献)和FADα(1)(来自蛋白质结合的FAD的贡献)增加(p
Optical metabolic imaging measures fluorescence intensity and lifetimes from metabolic cofactors nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FAD). These molecular level measurements provide unique biomarkers for early cellular responses to cancer treatments. Head and neck squamous cell carcinoma (HNSCC) is an attractive target for optical imaging because of easy access to the site using fiber optic probes. Two HNSCC cell lines, SCC25 and SCC61, were treated with Cetuximab (anti-EGFR antibody), BGT226 (PI3K/mTOR inhibitor), or cisplatin (chemotherapy) for 24 hours. Results show increased redox ratio, NADH alpha(1) (contribution from free NADH), and FAD alpha(1) (contribution from protein-bound FAD) for malignant cells compared with the nonmalignant cell line OKF6 (p